Your browser doesn't support javascript.
loading
[Not Available]. / Niveau de preuve du suivi thérapeutique pharmacologique des aminosides.
Venisse, Nicolas; Boulamery, Audrey.
  • Venisse N; Service de Toxicologie et Pharmacocinétique, CHU, Poitiers, France. Electronic address: n.venisse@chu-poitiers.fr.
  • Boulamery A; Laboratoire de Pharmacologie Médicale et Clinique, CHU, Marseille, France.
Therapie ; 66(1): 39-44, 2011.
Article en Fr | MEDLINE | ID: mdl-27393463
Aminoglycosides are major antibiotics indicated for the treatment of infection with gram-negative bacilli. They are characterized by high clinical effectiveness but their main drawback is the occurrence of toxicity in a significant number of patients. Pharmacokinetic parameters of aminoglycosides exhibit wide inter-individual variability and the relationships between concentration and effect have been clearly demonstrated. Consistent studies have demonstrated that therapeutic drug monitoring (TDM) of aminoglycosides administered in multiple daily doses was cost-effective in maximising antibiotic efficacy and/or reducing incidence of toxicity. Therefore TDM of aminoglycosides should be considered "essential". Level of evidence for TDM of aminoglycosides administered once daily is not so clearly demonstrated however it should be highly recommended.
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: Fr Año: 2011 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: Fr Año: 2011 Tipo del documento: Article